Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms-Reference-Cited by-同舟云学术

Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms

Published:2018-01 Issue: Volume:191 Page:70-79
ISSN:0920-9964
Container-title:Schizophrenia Research
language:en
Short-container-title:Schizophrenia Research

Author:

Kantrowitz Joshua T.,Epstein Michael L.,Lee Migyung,Lehrfeld Nayla,Nolan Karen A,Shope Constance,Petkova Eva,Silipo Gail,Javitt Daniel C.

Funder

NIH

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference93 articles.

1. Specificity of the Calgary Depression Scale for Schizophrenics;Addington;Schizophr. Res.,1994

2. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia;Alberati;Neuropharmacology,2012

3. Efficacy and safety of adjunctive bitopertin (5 and 10mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics—results from the phase III DayLyte study;Arango;Schizophr. Res.,2014

4. The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond;Balu;Curr. Opin. Pharmacol.,2015

5. Efficacy and safety of adjunctive bitopertin (10 and 20mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics—results from the Phase III FlashLyte Study;Blaettler;Schizophr. Res.,2014

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia;Schizophrenia Research;2024-08

2. Finding the right dose: NMDAR modulating treatments for cognitive and plasticity deficits in schizophrenia and the role of pharmacodynamic target engagement;Biological Psychiatry;2024-08

3. Decreased free D-aspartate levels in the blood serum of patients with schizophrenia;Frontiers in Psychiatry;2024-07-10

4. Integration of proteinogenic amino acids in the pathogenesis of schizophrenia;Medicine Advances;2024-06

5. Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments;Pharmacopsychiatry;2024-05-06